Last update 19 Jun 2024

CNV-2197944

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CNV 2197944, CNV2197944
Target
Cav2.2
Mechanism
Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers)
Therapeutic Areas
Nervous System DiseasesEndocrinology and Metabolic Disease
Active Indication
Diabetic NeuropathiesNeuralgia, Postherpetic
Inactive Indication
Diabetic peripheral neuropathy
Originator Organization
GSK PlcGSK Plc
Active Organization
GSK PlcGSK PlcBiogen, Inc.Biogen, Inc.
Inactive Organization
Convergence Pharmaceuticals, Inc.Calchan Ltd.Calchan Ltd.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Related

6
Clinical Trials associated with CNV-2197944
EUCTR2013-000407-16-PL / Not yet recruitingNot Applicable
A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy
EUCTR2013-000407-16-BG / Not yet recruitingNot Applicable
A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy
NCT01893125 / CompletedPhase 2
A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy
100 Clinical Results associated with CNV-2197944
Login to view more data
100 Translational Medicine associated with CNV-2197944
Login to view more data
100 Patents (Medical) associated with CNV-2197944
Login to view more data
100 Deals associated with CNV-2197944
Login to view more data

External Link

KEGGWikiATCDrug Bank
---
DB15229

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic peripheral neuropathyPhase 2
HU
Convergence Pharmaceuticals, Inc.
01 Aug 2013
NeuralgiaPhase 2
HU
Convergence Pharmaceuticals, Inc.
01 Aug 2013
Diabetic NeuropathiesPhase 2
HU
Calchan Ltd.
12 May 2013
Neuralgia, PostherpeticPhase 2
ZA
Calchan Ltd.
19 Mar 2013
PainPhase 1
GB
Calchan Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free